PROG News and Press, Progenity Inc. From 10/24/22

NEW YORK, NY / ACCESSWIRE / October 24, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PROG Holdings, Inc. ("PROG" or the "Company") (NYSE:PRG). If you suffered losses exceeding $50,000 investing in PROG stock or options ...

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generat...

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity’s management will host a webcast and confer...

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operati...

Biotechnology company Progenity (NASDAQ: PROG) is changing its name to Biora Therapeutics during Q2, 2022, to better reflect its focus on biotherapeutics. The legal name change is expected to be completed on or about April 26, 2022. The company's NASDAQ ticker symbol will change fro...

SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will change its name to Biora Therapeutics, Inc. during the second quarte...

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic thera...

The optimism on Wall Street continued during Tuesday's session, as the Nasdaq led the major U.S. equity indices higher yet again. As a result, the S&P 500 recorded its first close above 4,600 since mid-January. While the overall market pushed higher, in part on hopeful signs out of peace ...

Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...

Gainers: IGM Biosciences IGMS +37%. TRxADE HEALTH MEDS +21%. Ginkgo Bioworks DNA +14%. NexImmune NEXI +13%. BioSig Technologies (BSGM) +8%. Losers: NeoGenomics NEO -34%. Progenity PROG -25%. Aveanna Healthcare (AVAH) -21%. Kala Pharmaceuticals...